Clinical Trial Update: Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating tovorafenib (DAY101) alone or with pimasertib for melanoma and other solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Pilocytic Astrocytoma

Drugs mentioned

• DAY101 (tovorafenib)
• Pimasertib (pimasertib)

Snippet

Sponsor: Day One Biopharmaceuticals, Inc. | Conditions: Melanoma, Solid Tumor | Phase 1 | Status: TERMINATED